Archived Medical News Stories

RSSArchived Drug Trial News Stories - December 2009

Date Title Comments Rating
2009-12-31 FDA evaluates Phase III randomized trial in acute myeloid leukemia 0 None
2009-12-30 Santarus submits rifamycin SV MMX IND to the FDA 0 None
2009-12-30 Phase 3 trial of figitumumab discontinued by Pfizer 0 None
2009-12-29 Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer 0 None
2009-12-29 Promising results from Soligenix' RiVax vaccine against ricin toxin 0 None
2009-12-28 SVA submits the first clinical trial application for HFMD vaccine in China 0 None
2009-12-24 SemBioSys Genetics' Apo AI(Milano) program progress update 0 None
2009-12-24 Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor 0 None
2009-12-24 Merck discontinues MK-1903 niacin receptor agonist development program with Arena Pharmaceuticals 0 5
2009-12-23 Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST 0 None
2009-12-23 Positive results from Alimera Sciences' Iluvien FAME trial for DME 0 4.5
2009-12-23 Rigel Pharmaceuticals announces milestone payment from Daiichi Sankyo 0 None
2009-12-23 Compugen, Pfizer enter into multi-target collaboration 0 None
2009-12-23 ARCA biopharma submits Gencaro trial protocol for review under the FDA’s SPA process 0 None
2009-12-23 US Phase 2 clinical trial of RVX-208 commenced by Resverlogix 0 None
2009-12-22 Eritoran well tolerated in Phase II trial for severe sepsis 0 None
2009-12-22 Effectiveness of Genfit’s GFT505 clinical drug candidate questioned 0 None
2009-12-22 Study results of CSL’s pandemic H1N1 2009 vaccine published in JAMA 0 None
2009-12-22 DSM BioSolutions to manufacture Mayoly Spindler's 'MS1819' lipase biotherapeutic 0 None
2009-12-22 LEO Pharma announces positive results for two Phase III AK clinical trials 0 None
2009-12-21 Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported 0 None
2009-12-21 Oxford Finance to provide Titan Pharmaceuticals a $3M term loan 0 None
2009-12-21 Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study 0 None
2009-12-21 Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV 1 5
2009-12-21 Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy 0 None
2009-12-21 OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries 0 3
2009-12-21 CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial 0 None
2009-12-21 Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor 0 None
2009-12-21 Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study 0 2.3
2009-12-21 Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial 0 None
2009-12-21 Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention 0 None
2009-12-21 Preliminary results from Phase III study of afamelanotide in EPP announced 1 None
2009-12-18 Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials 0 None
2009-12-18 U.S. health officials announce shift in focus of prep trial in Botswana 0 None
2009-12-18 PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study 0 None
2009-12-18 Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV 0 None
2009-12-18 Initial data from REVLIMID Phase III trial in multiple myeloma patients announced 0 None
2009-12-18 Phase 2 clinical study of STA-9090 in NSCLC initiated 0 None
2009-12-18 ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus 0 None
2009-12-17 Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67 0 None
2009-12-17 Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences 0 None
2009-12-17 AlphaRx, Venturepharm sign supply agreement for ARX1088's API 0 None
2009-12-17 Positive results from DURECT's Phase IIb POSIDUR clinical trial for post-surgical pain 0 None
2009-12-17 Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts 0 None
2009-12-17 Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV 0 None
2009-12-17 BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint 0 None
2009-12-17 Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial 0 None
2009-12-17 Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients 0 2
2009-12-17 Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced 0 None
2009-12-16 Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals 1 None
2009-12-16 NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound 0 1
2009-12-16 Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals 0 None
2009-12-16 ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA 0 None
2009-12-16 Advanced Life Sciences Holdings' Restanza promising against tularemia 0 None
2009-12-16 Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine 0 None
2009-12-16 Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study 0 None
2009-12-16 Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer 0 None
2009-12-16 Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects 0 None
2009-12-16 Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression 0 None
2009-12-16 Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial 1 None
2009-12-16 Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected 0 5
2009-12-16 Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research 0 None
2009-12-16 ThromboGenics completes enrollment in second microplasmin Phase III trial 0 None
2009-12-15 DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment 0 None
2009-12-15 BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP 0 None
2009-12-15 Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001 0 None
2009-12-15 Positive results from study comparing exenatide once weekly to BYETTA 0 3
2009-12-15 Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody 0 None
2009-12-15 Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel 0 4
2009-12-15 University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer 0 None
2009-12-15 Encouraging results from DAVANAT in combination with chemotherapies and biologics 0 None
2009-12-15 Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis 0 None
2009-12-15 Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore 0 None
2009-12-15 QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients 0 None
2009-12-15 Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin 0 None
2009-12-15 Molecular Partners closes its CHF 46 million Series B equity investment round 0 None
2009-12-15 Update on new clinical developments and other initiatives related to Ceplene 0 None
2009-12-15 Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified 0 None
2009-12-15 Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints 0 None
2009-12-15 Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented 0 None
2009-12-14 Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers 0 3.5
2009-12-14 Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer 0 5
2009-12-14 AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection 0 None
2009-12-14 Pfizer announces results from studies evaluating neratinib 0 None
2009-12-14 Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented 0 None
2009-12-14 Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin 1 5
2009-12-14 Combination therapy improves overall survival in women with advanced breast cancer 0 None
2009-12-14 Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495 0 None
2009-12-14 Genentech announces positive results from Phase II study of T-DM1 1 None
2009-12-14 Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839 0 None
2009-12-14 ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data 0 None
2009-12-13 Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics 0 None
2009-12-13 Positive interim results of ARRY-380 in Phase 1 trial announced 0 None
2009-12-13 Clinical trial of 2009 H1N1 influenza vaccine 0 None
2009-12-12 Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced 0 None
2009-12-12 Phase 1 clinical trial of iCo-007 demonstrates positive safety profile 0 None
2009-12-11 Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences 0 None
2009-12-11 Zevalin clinical data presented at 2009 ASH meeting 0 None
2009-12-11 Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics 0 1
2009-12-11 Pfizer announces IES analysis of Aromasin in breast cancer recurrence 0 None
2009-12-11 ThromboGenics initiates Phase II trial of microplasmin for wet AMD 0 None
2009-12-11 Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA 0 None
2009-12-11 Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients 0 None
2009-12-11 Initiation of multi-national Phase III study of Stimuvax announced 0 1
2009-12-11 DMC recommends Novartis and Nordic Bioscience to continue oral calcitonin Phase III studies 0 None
2009-12-11 Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer 0 None
2009-12-10 Positive results from BioAlliance Pharma's acyclovir Lauriad phase III trial 0 None
2009-12-10 FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study 0 None
2009-12-10 DMC recommends Emisphere Technologies' to proceed with oral calcitonin trial for OP and OA 0 None
2009-12-10 Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia 0 None
2009-12-10 Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC 0 1
2009-12-10 Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA 0 4
2009-12-10 Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals 0 None
2009-12-10 Fourth-quarter and full year fiscal 2009 results announced by Biodel 0 None
2009-12-10 Immune-based treatment promising for AD 0 None
2009-12-10 Rituxan improves patients with previously untreated CLL, shows Phase III study CLL8 0 None
2009-12-10 Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences 0 None
2009-12-10 Initiation of dose-finding study to evaluate safety and efficacy of MP4OX treatment 0 None
2009-12-10 Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated 0 None
2009-12-09 Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced 0 None
2009-12-09 Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium 0 None
2009-12-09 RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352 0 None
2009-12-09 Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment 0 None
2009-12-09 Osteologix to file an European Marketing Application for its NB S101 strontium therapy 0 None
2009-12-09 Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented 0 None
2009-12-09 Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences 0 5
2009-12-09 Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML 0 None
2009-12-09 VERTICAL Phase II trial results for NHL released 0 5
2009-12-09 Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma 0 None
2009-12-09 Memgen announces positive clinical data of ISF35 with chemotherapy 0 None
2009-12-09 TGen and Scottsdale Healthcare test PHA-848125ac drug for thymic cancer 0 None
2009-12-09 University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle 0 None
2009-12-09 Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented 0 None
2009-12-09 Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study 0 None
2009-12-09 Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience 0 None
2009-12-09 Phase II clinical trial results of Doxorubicin Transdrug announced 0 None
2009-12-09 GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma 0 None
2009-12-09 Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients 0 None
2009-12-08 Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented 0 None
2009-12-08 Micromet presents final data from its blinatumomab Phase 2 study for ALL 0 None
2009-12-08 The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children 0 None
2009-12-08 Updated data from Allos Therapeutics' ongoing FOLOTYN study 0 None
2009-12-08 Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia 0 3
2009-12-08 Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint 0 None
2009-12-08 Interim data from Geron's GRNVAC1 phase II trial for AML presented 0 None
2009-12-08 Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma 0 None
2009-12-08 Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting 0 None
2009-12-08 Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma 0 None
2009-12-08 Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma 0 None
2009-12-08 Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced 0 5
2009-12-08 Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS 0 5
2009-12-08 Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients 0 None
2009-12-08 SOLESTA pivotal study meets primary endpoints for fecal incontinence treatment 0 None
2009-12-08 Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL 0 None
2009-12-08 Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML 0 None
2009-12-08 Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy 0 None
2009-12-08 Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations 0 None
2009-12-08 ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma 0 None
2009-12-08 Gentium presents evaluation results of Defibrotide for VOD at the ASH conference 0 None
2009-12-08 Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients 0 None
2009-12-08 Galapagos NV receives milestone payment to initiate Phase I clinical trial of GLPG0555 drug 0 None
2009-12-08 Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients 0 None
2009-12-08 Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009 0 None
2009-12-08 PolyMedix to present data on its heptagonist compounds 0 None
2009-12-08 Amgen announces results from first Phase 1/2 study of Nplate 0 None
2009-12-08 CAM314 randomized Phase 3 clinical trial results released 0 5
2009-12-08 Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported 0 None
2009-12-08 Phase II clinical trial results reveal positive effects of omacetaxine against CML 0 None
2009-12-08 Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting 0 None
2009-12-08 Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients 0 None
2009-12-08 Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA 0 None
2009-12-08 Phase 1 study results of TRU-016 in patients with CLL announced 0 None
2009-12-07 Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced 0 None
2009-12-07 Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported 0 None
2009-12-07 New data from Allos Therapeutics' FOLOTYN trial for PTCL 0 None
2009-12-07 Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented 0 None
2009-12-07 Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients 0 5
2009-12-07 Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting 0 None
2009-12-07 Synta Pharmaceuticals announces study results of elesclomol 0 None
2009-12-07 Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH 0 None
2009-12-07 Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin 0 None
2009-12-07 Micromet to present new data from its blinatumomab Phase 1 trial at the ASH meeting 0 None
2009-12-07 UCB presents data on Vimpat AED at AES meeting 0 None
2009-12-07 Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology 0 None
2009-12-07 Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin 0 None
2009-12-07 Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting 0 None
2009-12-07 J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism 0 None
2009-12-07 Positive clinical data from Phase II study of elacytarabine in patients with AML reported 0 None
2009-12-07 Updated results from phase III EXTEND clinical trial of pixantrone released 0 None
2009-12-07 Phase I/II clinical trial of Multimeric-001 Universal Flu Vaccine successful 0 None
2009-12-07 ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting 0 None
2009-12-07 Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced 0 None
2009-12-07 Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics 0 None
2009-12-07 Researchers explore optimal induction therapies for managing blood cancer 0 None
2009-12-07 VELCADE based regimens are cost-effective for payers and patients, finds study 0 None
2009-12-07 New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported 0 None
2009-12-07 Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris 0 None
2009-12-07 Amgen announces results from three studies on the safety and efficacy of Nplate 0 None
2009-12-07 Updated safety data from Phase 2b 003-A1 study of carfilzomib announced 0 None
2009-12-06 ImmunoGen reports encouraging clinical data of IMGN901 0 None
2009-12-06 Positive final data from Phase 2 study of ISTODAX presented 0 None
2009-12-06 Dabigatran etexilate offers effective therapy to prevent recurrent VTE 0 None
2009-12-06 Bortezomib can improve control of GVHD and immune system recovery 0 None
2009-12-05 Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI 0 None
2009-12-04 Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting 0 None
2009-12-04 Results from Phase III pivotal study of FIRMAGON presented 0 None
2009-12-04 Pfizer to present study findings from its expanded breast cancer portfolio 0 None
2009-12-04 Preclinical data of Curis' HSP 90 inhibitor published 0 None
2009-12-04 Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN 0 None
2009-12-04 Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel 0 None
2009-12-04 Genzyme announces reopening of enrollment in its Pompe disease ATAP program 0 None
2009-12-03 Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial 0 None
2009-12-03 Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial 0 None
2009-12-03 iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference 0 None
2009-12-03 Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist 0 None
2009-12-03 Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial 0 None
2009-12-03 Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC 0 None
2009-12-03 Tripep receives approval to extend ChronVac-C study 0 None
2009-12-03 More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented 0 None
2009-12-03 European Phase III clinical trial of budesonide MMX completes patient enrollment 0 None
2009-12-02 Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study 0 None
2009-12-02 FDA grants Fast Track designation for AEterna Zentaris' perifosine 0 None
2009-12-02 Genta to supply Ganite for new CF clinical trial 0 None
2009-12-02 Sepracor to present clinical study data of STEDESA at the 2009 AES meeting 0 None
2009-12-02 New data demonstrating the strength of Novartis' hematology portfolio to be presented 0 None
2009-12-02 University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration 0 None
2009-12-02 Updated results from MYTHOS clinical trial of RenalGuard presented at AHA meeting 0 None
2009-12-02 Roche announces results of phase III taspoglutide study in diabetes patients 0 2
2009-12-02 Results from second Phase III placebo controlled study of EXPAREL announced 0 4
2009-12-02 Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics 0 None
2009-12-02 New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented 0 None
2009-12-02 Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting 0 None
2009-12-02 Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118 0 None
2009-12-01 CRO to run CEL-SCI's upcoming Phase III clinical trial 0 None
2009-12-01 Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting 0 None
2009-12-01 Palatin Technologies issued U.S. patent covering its lead heart failure drug candidate 0 None
2009-12-01 Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat 0 None
2009-12-01 Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed 0 5
2009-12-01 Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials 0 None
2009-12-01 StemCyte concludes exclusive license and commercialization agreement with Academia Sinica 0 None
2009-12-01 Amgen to present updated data on Nplate at the 2009 ASH meeting 0 5
2009-12-01 Completion of Phase I study of CPSI-2364 announced by Cytokine PharmaSciences 0 None
2009-12-01 University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment 0 None
2009-12-01 ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro 0 None


244 posts
34 raters